CA2948876A1 - Imidazole derivatives as formyl peptide receptor modulators - Google Patents

Imidazole derivatives as formyl peptide receptor modulators Download PDF

Info

Publication number
CA2948876A1
CA2948876A1 CA2948876A CA2948876A CA2948876A1 CA 2948876 A1 CA2948876 A1 CA 2948876A1 CA 2948876 A CA2948876 A CA 2948876A CA 2948876 A CA2948876 A CA 2948876A CA 2948876 A1 CA2948876 A1 CA 2948876A1
Authority
CA
Canada
Prior art keywords
unsubstituted
alkyl
substituted
substituent
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2948876A
Other languages
English (en)
French (fr)
Inventor
Richard L. Beard
Tien T. Duong
Michael E. Garst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CA2948876A1 publication Critical patent/CA2948876A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2948876A 2014-05-21 2015-05-21 Imidazole derivatives as formyl peptide receptor modulators Abandoned CA2948876A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462001188P 2014-05-21 2014-05-21
US62/001,188 2014-05-21
PCT/US2015/032069 WO2015179707A1 (en) 2014-05-21 2015-05-21 Imidazole derivatives as formyl peptide receptor modulators

Publications (1)

Publication Number Publication Date
CA2948876A1 true CA2948876A1 (en) 2015-11-26

Family

ID=53276329

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2948876A Abandoned CA2948876A1 (en) 2014-05-21 2015-05-21 Imidazole derivatives as formyl peptide receptor modulators

Country Status (12)

Country Link
US (2) US10301269B2 (https=)
EP (1) EP3145916B1 (https=)
JP (1) JP6660889B2 (https=)
KR (1) KR20170005121A (https=)
CN (1) CN106458921B (https=)
AU (2) AU2015264021B2 (https=)
BR (1) BR112016027133A8 (https=)
CA (1) CA2948876A1 (https=)
DK (1) DK3145916T3 (https=)
ES (1) ES2788700T3 (https=)
RU (1) RU2748652C2 (https=)
WO (1) WO2015179707A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
AU2012329098B2 (en) 2011-10-26 2017-08-03 Allergan, Inc. Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
KR102223384B1 (ko) * 2013-03-06 2021-03-05 알러간, 인코포레이티드 피부 질환 치료용 포르밀 펩티드 수용체 2의 항진제의 용도
RU2703725C1 (ru) 2013-11-21 2019-10-22 Аллерган, Инк. Производные фенилкарбамата в качестве модуляторов формилпептидного рецептора
WO2015179707A1 (en) 2014-05-21 2015-11-26 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators
EP3442950A1 (en) * 2016-04-12 2019-02-20 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533210A1 (fr) 1982-09-17 1984-03-23 Lyon I Universite Claude Edulcorants de synthese
AU2004290368A1 (en) 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, FPRL1, as a tool for identifying compounds effective in the treatment of pain and inflammation
JP4834840B2 (ja) * 2004-01-06 2011-12-14 ノヴォ ノルディスク アー／エス ヘテロアリール尿素およびグルコキナーゼ活性化剤としてのその使用
WO2007086584A1 (ja) * 2006-01-30 2007-08-02 Meiji Seika Kaisha, Ltd. 新規ＦａｂＫおよびＦａｂＩ／Ｋ阻害剤
MX2009002046A (es) * 2006-08-24 2009-03-06 Astrazeneca Ab Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos.
WO2009000748A1 (en) 2007-06-27 2008-12-31 Solvay Fluor Gmbh Preparation of compounds with a perfluoroalkylsulfonyl group
CA2692945A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Compounds - 945
CN101998680B (zh) * 2009-08-24 2016-01-13 中兴通讯股份有限公司 帧序列号的发送方法及节点b和服务无线网络控制器
CA2819457A1 (en) 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
EP2673263A1 (en) 2011-02-11 2013-12-18 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators
EP2731931A1 (en) 2011-07-11 2014-05-21 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators
AU2012329098B2 (en) * 2011-10-26 2017-08-03 Allergan, Inc. Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8541577B2 (en) 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
EP2814815A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators
ES2711363T3 (es) 2012-04-16 2019-05-03 Allergan Inc Derivados de (2-ureidoacetamido)alquilo como moduladores del receptor 2 de péptidos formilados
AU2014225992B2 (en) 2013-03-06 2018-03-22 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
KR102223384B1 (ko) 2013-03-06 2021-03-05 알러간, 인코포레이티드 피부 질환 치료용 포르밀 펩티드 수용체 2의 항진제의 용도
RU2696581C2 (ru) 2013-07-16 2019-08-05 Аллерган, Инк. Производные n-мочевинозамещенных аминокислот как модуляторы формил-пептидного рецептора
RU2703725C1 (ru) 2013-11-21 2019-10-22 Аллерган, Инк. Производные фенилкарбамата в качестве модуляторов формилпептидного рецептора
US9920013B2 (en) 2014-01-29 2018-03-20 Allergan, Inc. 2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators
US9604934B2 (en) 2014-01-29 2017-03-28 Allergan, Inc. Urea hydantoin derivatives as formyl peptide modulators
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
WO2015179707A1 (en) 2014-05-21 2015-11-26 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators
CN109715602A (zh) 2016-03-28 2019-05-03 阿勒根公司 苯基脲衍生物作为n-甲酰肽受体调节剂
EP3442950A1 (en) 2016-04-12 2019-02-20 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators

Also Published As

Publication number Publication date
WO2015179707A1 (en) 2015-11-26
EP3145916A1 (en) 2017-03-29
KR20170005121A (ko) 2017-01-11
CN106458921B (zh) 2020-03-24
ES2788700T3 (es) 2020-10-22
AU2020203420A1 (en) 2020-06-11
US10800744B2 (en) 2020-10-13
US10301269B2 (en) 2019-05-28
US20170096401A1 (en) 2017-04-06
BR112016027133A2 (pt) 2017-08-15
RU2016145596A3 (https=) 2018-11-19
AU2015264021B2 (en) 2020-02-27
BR112016027133A8 (pt) 2021-06-29
AU2020203420B2 (en) 2021-12-16
EP3145916B1 (en) 2020-02-12
CN106458921A (zh) 2017-02-22
JP6660889B2 (ja) 2020-03-11
RU2748652C2 (ru) 2021-05-28
JP2017520528A (ja) 2017-07-27
AU2015264021A1 (en) 2016-12-01
DK3145916T3 (da) 2020-05-11
RU2016145596A (ru) 2018-06-21
US20200115346A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
AU2020203420B2 (en) Imidazole derivatives as formyl peptide receptor modulators
AU2012336013C1 (en) Aryl urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
US9670150B2 (en) (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
AU2014290618B2 (en) Derivatives of N-urea substituted amino acids as formyl peptide receptor modulators
EP3331897B1 (en) Phenyl urea analogs as formyl peptide receptor 1 (fpr1) selective agonists
US9926264B2 (en) Phenylcarbamate derivatives as formyl peptide receptor modulators
US9604934B2 (en) Urea hydantoin derivatives as formyl peptide modulators
WO2015042071A1 (en) Diphenyl urea derivatives as formyl peptide receptor modulators
US9868700B2 (en) Carbamoyl hydrazine derivatives as formyl peptide modulators
US9920013B2 (en) 2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators
AU2021261917A1 (en) Phenyl urea derivatives as N-formyl peptide receptor modulators

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200424

FZDE Discontinued

Effective date: 20230411